News & Videos - BAVARIAN NORDIC A S BVNKF

COPENHAGEN, Denmark, November 12, 2021 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Paul Chaplin 2. Reason for the notification a) Position/status President and Chief Executive Officer of Bavarian...

COPENHAGEN, Denmark , November 12, 2021 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2021 and business progress for the third quarter of 2021. Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: “We continued to experience a challenging market environment for our travelers vaccine business during the third quarter, due to COVID-19. Despite these headwinds, we remain on track to meet our guidance as both...

COPENHAGEN, Denmark, November 1, 2021 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transaction of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. The transaction concerns the vesting of restricted stock units, awarded to the Company’s Executive Vice President and Chief Financial Officer, Henrik Juuel, as part of a sign-on bonus upon assuming his position on...

COPENHAGEN, Denmark, September 24, 2021 – Bavarian Nordic A/S (OMX: BAVA) announced today that the funding agreement recently entered with the Danish Ministry of Health to further advance the development of ABNCoV2, the Company’s COVID-19 vaccine candidate, has now been approved by the Finance Committee of the Danish Parliament, thereby finally executing the agreement. For detailed information about the agreement, see company announcement no. 27/2021 . About Bavarian Nordic Bavarian Nordic...

COPENHAGEN, Denmark, September 16, 2021 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transaction of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. The transaction concerns the exercise of warrants by Thomas Bennekov, who has served as an employee-elected member of the Board of Directors of Bavarian Nordic since April 2021. The warrants were awarded to Mr....

COPENHAGEN, Denmark, September 10, 2021 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Henrik Birk 2. Reason for the notification a) Position/status Executive Vice President and Chief Operating Officer...

Updated Articles of Association for Bavarian Nordic A/S. Attachment Bavarian Nordic - Articles of Association...

COPENHAGEN, Denmark, September 8, 2021 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 2,478,690 as a consequence of employees’ exercise of warrants. The capital increase was effected without any pre-emption rights for the existing shareholders of the Company or others. The shares were subscribed for in cash at the following prices per share of nominally DKK 10: 100,152 shares at DKK 205.80 and 147,717 shares at DKK...

Study achieved the primary endpoint by demonstrating a statistically significant reduction in viral load in vaccinated versus control (placebo) treated volunteers Demonstrated up to a 79% efficacy in reducing symptomatic RSV infections Management will host a conference call today at 2 pm CET (8 am EST) to review the results COPENHAGEN, Denmark, September 1, 2021 – Bavarian Nordic A/S (OMX: BAVA) announced today results from a human challenge trial of the RSV vaccine candidate, MVA-BN ® RSV....

COPENHAGEN, Denmark , August 25, 2021 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first half of 2021 and releases its financial calendar for 2022. Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: “We are very pleased to confirm the successful execution of our commercial strategy with nearly 30 Rabipur/RabAvert and Encepur markets now transferred to Bavarian Nordic. Our objective during this transition...

Based on successfully achieving certain milestones primarily related to the execution of a Phase 3 trial and development of large-scale manufacturing processes, Bavarian Nordic will be eligible to receive up to DKK 800 million Agreement aims to strengthen reliability and security of supply of COVID-19 vaccines to meet future revaccination demands COPENHAGEN, Denmark, August 23, 2021 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company has entered a funding agreement with the...

Phase 2 trial will investigate vaccine’s ability to boost existing immunity from prior COVID-19 vaccination or disease Immune responses against circulating SARS-CoV2 variants will also be assessed Preparations ongoing to support Phase 3 development COPENHAGEN, Denmark, August 23, 2021 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a Phase 2 clinical trial of its COVID-19 vaccine candidate, ABNCoV2. The trial will investigate the potential of ABNCoV2 as a booster vaccine...

Vaccine was well tolerated across all dose groups with no observed difference in adverse event profile after first and second vaccination Strong booster effect demonstrated after second vaccination with antibody titers above levels detected in humans after COVID-19 disease and neutralization titers significantly above those reported for currently approved SARS-CoV-2 vaccines Strong cross neutralization of SARS-CoV2 variants, including the Delta variant COPENHAGEN, Denmark, August 9, 2021 –...

COPENHAGEN, Denmark, June 11, 2021 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company was recently engaged by Public Health England (PHE) and the Medicines and Health Products Regulatory Agency (MHRA) to supply its IMVANEX ® smallpox vaccine in response to new cases of monkeypox in the UK. Two related cases were confirmed and admitted to a hospital in Liverpool. One was most likely infected in Africa, where the family arrived from a few days before onset of disease, and a...

Updated Articles of Association for Bavarian Nordic A/S. Attachment Bavarian Nordic - Articles of Association...

COPENHAGEN, Denmark, June 10, 2021 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Henrik Birk 2. Reason for the notification a) Position/status Executive Vice President and Chief Operating...

COPENHAGEN, Denmark, June 10, 2021 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Company's share capital has been increased by nominally DKK 804,440 as a consequence of employees’ exercise of warrants. The capital increase was effected without any pre-emption rights for the existing shareholders of the Company or others. A total of 80,444 new shares were subscribed for in cash at DKK 205.80 per share of nominally DKK 10. The total proceeds to Bavarian Nordic A/S from...

COPENHAGEN, Denmark, June 2, 2021 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announces that the share buy-back program, which was announced and initiated on May 27, 2021, has now been terminated, as the intended number of shares under the program has been repurchased. The program was executed in accordance with the provisions of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse and supplementing Regulation (EU) 2016/1052 of 8 March...

COPENHAGEN, Denmark, May 27, 2021 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the initiation of a new share buy-back program, under which the Company intends to buy back up to 31,747 of its own shares. The purpose of the share buy-back program is to meet the Company’s obligations arising from the share-based incentive programs for the Board of Directors and Executive Management, in accordance with the Company’s remuneration policy. The share buy-back program is initiated...

COPENHAGEN, Denmark, May 27, 2021 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its interim financial results and business progress for the first three months of 2021. Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: “It has been an eventful quarter for Bavarian Nordic with continued progress in the commercialization of the Company. This is driven by the acquired product portfolio from GSK, our smallpox vaccine business, and several new supply...